Suppr超能文献

口腔鳞状细胞癌中 3'-脱氧-3'-18F-氟代胸腺嘧啶 PET 的组织病理学验证。

Histopathologic validation of 3'-deoxy-3'-18F-fluorothymidine PET in squamous cell carcinoma of the oral cavity.

机构信息

Department of Radiation Oncology, Institute of Oncology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands.

出版信息

J Nucl Med. 2010 May;51(5):713-9. doi: 10.2967/jnumed.109.071910. Epub 2010 Apr 15.

Abstract

UNLABELLED

Accelerated tumor cell repopulation is an important mechanism adversely affecting therapeutic outcome in head and neck cancer. The noninvasive assessment of the proliferative state of a tumor by PET may provide a selection tool for customized treatment. 3'-deoxy-3'-(18)F-fluorothymidine ((18)F-FLT) is a PET tracer that is phosphorylated by thymidine kinase 1 (TK-1) and, as such, reflects cellular proliferation. Before the use of (18)F-FLT PET for tumor characterization is accepted and introduced into clinical studies, validation against tumor histology is mandatory. The aim of this study was to validate (18)F-FLT PET in squamous cell carcinomas of the oral cavity using immunohistochemical staining for the proliferation marker iododeoxyuridine and for TK-1.

METHODS

Seventeen patients with primary squamous cell carcinomas of the oral cavity underwent an (18)F-FLT PET/CT scan before surgery, and iododeoxyuridine was administered 20 min before tumor resection. (18)F-FLT PET/CT scans were segmented, and PET/CT volumes and PET signal intensities were calculated (mean standardized uptake value [SUV(mean)] and maximum standardized uptake value [SUV(max)]). Multiple paraffin-embedded tumor sections were immunohistochemically stained for iododeoxyuridine and TK-1. For iododeoxyuridine, labeling indices and optical densities were calculated and correlated with SUV(mean) and SUV(max). TK-1 staining was visually and semiquantitatively assessed.

RESULTS

All primary tumors were identified with (18)F-FLT PET but with a large range in tracer uptake (mean SUV(max), 5.9; range, 2.2-15.2). Also, there was a large variability in iododeoxyuridine labeling indices (mean, 0.09; range, 0.01-0.29) and optical densities (mean, 28.2; range, 12.6-37.8). The iododeoxyuridine optical densities correlated significantly with SUV(mean) and SUV(max), but the labeling indices did not. In most tumors, TK-1 staining of varying intensity was present but correlated with neither iododeoxyuridine binding nor (18)F-FLT uptake.

CONCLUSION

The current study demonstrated only a weak correlation between (18)F-FLT uptake and iododeoxyuridine staining intensity in oral cavity tumors. This weak correlation may be explained by differences in biomarker characteristics, resolution, and quantification methods.

摘要

目的

使用增殖标志物碘脱氧尿苷(iododeoxyuridine)和胸苷激酶 1(thymidine kinase 1,TK-1)的免疫组织化学染色,验证口腔鳞状细胞癌中 3'-去氧-3'-[18F]氟代胸腺嘧啶(3'-deoxy-3'-(18)F-fluorothymidine,(18)F-FLT)正电子发射断层扫描(positron emission tomography,PET)在肿瘤特征描述中的应用。

方法

17 例口腔原发性鳞状细胞癌患者在手术前进行了 (18)F-FLT PET/CT 扫描,并在肿瘤切除前 20 分钟给予碘脱氧尿苷。对 (18)F-FLT PET/CT 扫描进行分割,并计算 PET/CT 容积和 PET 信号强度(平均标准化摄取值[mean standardized uptake value,SUV(mean)]和最大标准化摄取值[SUV(max)])。对多个石蜡包埋的肿瘤切片进行碘脱氧尿苷和 TK-1 的免疫组织化学染色。对于碘脱氧尿苷,计算标记指数和光密度,并与 SUV(mean)和 SUV(max)相关。TK-1 染色进行了视觉和半定量评估。

结果

所有原发性肿瘤均通过 (18)F-FLT PET 检测到,但示踪剂摄取范围较大(SUV(max)平均值为 5.9,范围为 2.2-15.2)。碘脱氧尿苷标记指数(mean 0.09,范围 0.01-0.29)和光密度(mean 28.2,范围 12.6-37.8)也存在很大的变异性。碘脱氧尿苷光密度与 SUV(mean)和 SUV(max)呈显著相关,但标记指数则不然。在大多数肿瘤中,存在不同强度的 TK-1 染色,但与碘脱氧尿苷结合或 (18)F-FLT 摄取均无相关性。

结论

本研究仅在口腔肿瘤中观察到 (18)F-FLT 摄取与碘脱氧尿苷染色强度之间存在微弱的相关性。这种弱相关性可能是由于生物标志物特征、分辨率和定量方法的差异所致。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验